Contributions of StyleSheetSybil

Contributions by StyleSheetSybil, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 12,877 edits includes activity predating the current log.

1. 10:02, 23 Jul 2026 (diff | hist) Talk:Asymchem Laboratories 611 +267 /* Notability, and the oldest registry record on the wiki */ reply
2. 22:29, 12 Jun 2026 (diff | hist) Sterility testing 4,776 ±0 m give the limit of quantitation with the signal-to-noise ratio it assumes
3. 23:28, 10 May 2026 (diff | hist) Growth hormone secretagogue 4,613 ±0 convert a hard-coded date to the house format
4. 22:36, 3 Mar 2026 (diff | hist) Placebo-adjusted effect 4,805 ±0 m expand §How figures are misreported
5. 04:07, 23 Oct 2025 (diff | hist) Grey market 4,068 ±0 m add the cross-link to the temperature-excursion article
6. 18:14, 25 Jul 2025 (diff | hist) Vial filling and stoppering 4,557 +545 correct the eutectic temperature — source gives a range
7. 13:02, 11 Jun 2025 (diff | hist) Talk:Shanghai Sigma-Audley New Material Technology 748 +222 /* Packaging consistency: observation or compliment? */ reply
8. 12:30, 11 May 2025 (diff | hist) Patent expiry and biosimilars 3,580 ±0 rm the speculation about future scheduling
9. 09:11, 7 May 2025 (diff | hist) Talk:Area percent purity 1,096 +74 /* Should the four unseen categories be a definition list? */ reply
10. 10:22, 6 May 2025 (diff | hist) Talk:Area percent purity 674 +200 /* Should the four unseen categories be a definition list? */ new section
11. 09:12, 24 Apr 2025 (diff | hist) SUSTAIN trial programme 4,187 ±0 m attribute the subgroup finding as exploratory
12. 09:31, 4 Apr 2025 (diff | hist) Talk:Shanghai Wibson Biotechnology 959 +180 /* A shorter registry history is not a finding */ reply
13. 09:03, 12 Feb 2025 (diff | hist) Talk:Hubei Jianxiang Bioscience 959 +169 /* Should the peptide-content explanation live here? */ reply
14. 11:22, 11 Feb 2025 (diff | hist) Talk:Lyophilisation 611 +402 /* Requested move: → Lyophilization */ reply
15. 09:47, 4 Feb 2025 (diff | hist) Talk:Research use only 537 +156 /* "Not approved" versus "unapproved" */ new section
16. 20:31, 23 Jan 2025 (diff | hist) Lixisenatide 2,936 +634 rm duplicated pharmacokinetics — the same figures appear in the infobox
17. 09:29, 21 Jan 2025 (diff | hist) USP General Chapter 71 2,254 ±0 m correct the water-content figure — the source reports it on a dry basis
18. 14:02, 15 Jan 2025 (diff | hist) Talk:Certificate of analysis 748 +286 /* The seven-field table */ reply
19. 01:09, 5 Jan 2025 (diff | hist) Analytical method validation 4,021 +18 add the forced-degradation conditions the claim rests on
20. 11:03, 27 Dec 2024 (diff | hist) Certificate of analysis 6,033 +336 m clarify that a signature on a certificate is a release, not a verification
21. 19:17, 24 Dec 2024 (diff | hist) Limit of detection 3,678 +131 add the counterion determination method by name
22. 10:18, 11 Nov 2024 (diff | hist) FLOW trial 2,601 +444 the article attributed a finding to the wrong trial in the programme
23. 06:35, 1 Nov 2024 (diff | hist) Liraglutide 3,273 +34 m label the animal data as animal data in the sentence, not only in the section heading
24. 20:17, 24 Oct 2024 (diff | hist) SURMOUNT trial programme 2,668 +101 expand §Scope of the evidence
25. 07:33, 31 Aug 2024 (diff | hist) Amylin 1,269 ±0 clarify that the peptide backbone is acylated rather than PEGylated